Yifan Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Yifan Pharmaceutical has a total shareholder equity of CN¥8.4B and total debt of CN¥2.5B, which brings its debt-to-equity ratio to 29.2%. Its total assets and total liabilities are CN¥12.4B and CN¥4.0B respectively. Yifan Pharmaceutical's EBIT is CN¥151.3M making its interest coverage ratio 2.5. It has cash and short-term investments of CN¥1.1B.
Key information
29.2%
Debt to equity ratio
CN¥2.46b
Debt
| Interest coverage ratio | 2.5x |
| Cash | CN¥1.08b |
| Equity | CN¥8.42b |
| Total liabilities | CN¥3.95b |
| Total assets | CN¥12.37b |
Recent financial health updates
Does Yifan Pharmaceutical (SZSE:002019) Have A Healthy Balance Sheet?
Oct 11
These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively
Jun 04Recent updates
Does Yifan Pharmaceutical (SZSE:002019) Have A Healthy Balance Sheet?
Oct 11Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Could Signal Some Risk
Sep 11These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively
Jun 04Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story
May 08A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price
Mar 01Financial Position Analysis
Short Term Liabilities: 002019's short term assets (CN¥3.9B) exceed its short term liabilities (CN¥3.0B).
Long Term Liabilities: 002019's short term assets (CN¥3.9B) exceed its long term liabilities (CN¥966.6M).
Debt to Equity History and Analysis
Debt Level: 002019's net debt to equity ratio (16.3%) is considered satisfactory.
Reducing Debt: 002019's debt to equity ratio has increased from 21.4% to 29.2% over the past 5 years.
Debt Coverage: 002019's debt is not well covered by operating cash flow (18.1%).
Interest Coverage: 002019's interest payments on its debt are not well covered by EBIT (2.5x coverage).